Bispecific Antibodies for Cancer Therapy: the Light at the End of the Tunnel?

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2010 Jan 16

PMID 20073127

Citations 124

Authors

Patrick Chames

Daniel Baty

Affiliations

Soon will be listed here.

Abstract

With 23 approvals in the US and other countries and four approvals outside US, antibodies are now widely recognized as therapeutic molecules. The therapeutic and commercial successes met by rituximab, trastuzumab, cetuximab and other mAbs have inspired antibody engineers to improve the efficacy of these molecules. Consequently, a new wave of antibodies with engineered Fc leading to much higher effector functions such as antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity is being evaluated in the clinic, and several approvals are expected soon. In addition, research on a different class of antibody therapeutics, bispecific antibodies, has recently led to outstanding clinical results, and the first approval of the bispecific antibody catumaxomab, a T cell retargeting agent that was approved in the European Union in April 2009. This review describes the most recent advances and clinical study results in the field of bispecific antibodies, a new class of molecules that might outshine conventional mAbs as cancer immunotherapeutics in a near future.

Citing Articles

Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy.

Zhao R, Fan X Int J Mol Sci. 2025; 26(4).

PMID: 40003906 PMC: 11855211. DOI: 10.3390/ijms26041440.

Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.

Jureczek J, Kalwak K, Dziegiel P Cancers (Basel). 2025; 16(24.

PMID: 39766080 PMC: 11674729. DOI: 10.3390/cancers16244181.

The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells.

Cho J, Tae N, Song Y, Kim C, Lee S, Ahn J Cancer Immunol Immunother. 2024; 73(10):196.

PMID: 39105814 PMC: 11303351. DOI: 10.1007/s00262-024-03785-4.

On-Demand Thio-Succinimide Hydrolysis for the Assembly of Stable Protein-Protein Conjugates.

Vasco A, Taylor R, Mendez Y, Bernardes G J Am Chem Soc. 2024; 146(30):20709-20719.

PMID: 39012647 PMC: 11295205. DOI: 10.1021/jacs.4c03721.

Contemporary Approaches to Immunotherapy of Solid Tumors.

Kuznetsova A, Glukhova X, Popova O, Beletsky I, Ivanov A Cancers (Basel). 2024; 16(12).

PMID: 38927974 PMC: 11201544. DOI: 10.3390/cancers16122270.

References

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel P, Schwenkenbecher J . A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000; 95(6):2098-103. View

Curnow R . Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother. 1998; 45(3-4):210-5. PMC: 11037766. DOI: 10.1007/s002620050435. View

Fury M, Lipton A, Smith K, Winston C, Pfister D . A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother. 2007; 57(2):155-63. PMC: 11030736. DOI: 10.1007/s00262-007-0357-5. View

Hartmann F, Renner C, Jung W, Da Costa L, Tembrink S, Held G . Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res. 2001; 7(7):1873-81. View

Ruf P, Jager M, Ellwart J, Wosch S, Kusterer E, Lindhofer H . Two new trifunctional antibodies for the therapy of human malignant melanoma. Int J Cancer. 2003; 108(5):725-32. DOI: 10.1002/ijc.11630. View

Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E . Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother. 2009; 32(4):341-52. DOI: 10.1097/CJI.0b013e31819b7c70. View

Lindhofer H, Mocikat R, Steipe B, Thierfelder S . Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol. 1995; 155(1):219-25. View

Chames P, Baty D . Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel. 2009; 12(2):276-83. View

10.

Repp R, Van Ojik H, Valerius T, Groenewegen G, WIELAND G, Oetzel C . Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer. 2003; 89(12):2234-43. PMC: 2395280. DOI: 10.1038/sj.bjc.6601367. View

11.

Baeuerle P, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4. DOI: 10.1158/0008-5472.CAN-09-0547. View

12.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

13.

Otz T, Grosse-Hovest L, Hofmann M, Rammensee H, Jung G . A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia. 2008; 23(1):71-7. DOI: 10.1038/leu.2008.271. View

14.

Grabert R, Cousens L, Smith J, Olson S, Gall J, Young W . Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006; 12(2):569-76. DOI: 10.1158/1078-0432.CCR-05-2005. View

15.

Grosse-Hovest L, Wick W, Minoia R, Weller M, Rammensee H, Brem G . Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer. 2005; 117(6):1060-4. DOI: 10.1002/ijc.21294. View

16.

Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee H, Jung G . A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol. 2003; 33(5):1334-40. DOI: 10.1002/eji.200323322. View

17.

McBride W, Zanzonico P, Sharkey R, Noren C, Karacay H, Rossi E . Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006; 47(10):1678-88. View

18.

Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A . Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res. 2005; 65(7):2882-9. DOI: 10.1158/0008-5472.CAN-04-2637. View

19.

Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M . Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother. 2007; 30(8):798-807. DOI: 10.1097/CJI.0b013e318156750c. View

20.

Howland K, Ausubel L, London C, Abbas A . The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol. 2000; 164(9):4465-70. DOI: 10.4049/jimmunol.164.9.4465. View